Death Vs. Symptomatic Relief – Weighing Risks And Benefits For Asthma Drugs
Executive Summary
When discussing a drug's benefits and risks, there is more to the equation than just death, Judith Kramer, Duke University, pointed out during a meeting of three FDA advisory committees to discuss asthma indications for long-acting beta agonists